LIMNW — Liminatus Pharma, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1971387 ·
Last close
—
Market Cap
—
52W High
—
52W Low
—
ADV30
—
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -1,100,898 | -1,123,714 | 2,790,249 | 1,907,674 | 2,922,845 |
| Dec 2025 | 0 | — | -884,211 | -8,168,927 | 512,795 | 337,655 | 10,327,485 |
| Sep 2025 | 0 | — | -701,170 | -1,823,351 | 1,342,409 | 724,502 | 2,988,172 |
| Jun 2025 | — | — | — | — | — | — | — |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$2,318,528,475
Investing CF
$-2,029,255,108
Financing CF
$-492,189,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
—
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-38,871,733
Inventory
—
Receivables
$0
ST Investments
—
EBIT TTM
$-10,077,857
Pretax Income TTM
$-10,221,842
Interest Exp TTM
$236,691
Analysts
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -2,967,812 | -10,206,517 | 512,795 | 10,327,485 | — | -9,963,318 |
| Dec 2024 | 0 | -3,329,953 | -3,546,309 | 5,408,859 | 24,748,922 | — | -1,451,066 |
| Dec 2023 | 0 | -4,819,000 | -4,984,000 | 2,242,000 | 18,036,000 | — | -3,345,000 |
| Dec 2022 | 0 | -2,709,000 | -2,928,000 | 6,843,000 | 17,653,000 | — | -869,000 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| AMGN | AMGEN INC | $181.31B | $335.94 | — |
| GILD | GILEAD SCIENCES, INC. | $166.04B | $133.73 | — |
| ARGX | ARGENX SE | $50.27B | $808.43 | — |
| RVMD | Revolution Medicines, Inc. | $32.93B | $154.89 | — |
| BIIB | BIOGEN INC. | $28.51B | $193.08 | — |
News headlines (Yahoo Finance, 1h cache)
Liminatus Pharma Announces Nasdaq Delisting Notification
2026-05-22 00:28 · Yahoo
Liminatus Pharma Announces Planned Phase 1 Clinical Trial of IBA101, a Next-Generation CD47 Blocking Antibody
2026-03-17 12:08 · Yahoo
Liminatus Pharma, Inc. Announces Pricing of $4.0 Million Public Offering
2026-02-17 13:44 · Yahoo
BC-Most Active Stocks
2026-02-09 15:30 · Yahoo
Liminatus Pharma, Inc. (NASDAQ: LIMN) Signs MOU with Capital Trust Group for USD 30 Million Equity Investment via an earn-out mechanism and Future Strategic Cooperation
2025-10-30 14:04 · Yahoo
BNB Falls Below $750 as Crypto Market Sell-Off Erases Corporate-Fueled Optimism
2025-08-05 16:11 · Yahoo
Liminatus Pharma Inc. Evaluates Formation of Digital Asset Investment Vehicle Targeting Up To $500 Million in Capital Strategies
2025-07-25 12:31 · Yahoo
Liminatus Pharma Inc. Takes Next Step in Evaluating Digital Asset-Linked Capital Strategy
2025-07-24 12:31 · Yahoo
Liminatus Pharma, Inc. Initiates Strategic Review of Blockchain-Integrated Treasury Strategy
2025-07-22 17:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.